These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7227218)

  • 1. Effect of razoxane (ICRF 159) on daunomycin (NSC 82151) metabolism and DNA complexation.
    Wang GM; Finch M
    Drug Chem Toxicol; 1980; 3(2):213-25. PubMed ID: 7227218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitigating effects of ICRF-159 (razoxane) on a daunomycin-induced cardiomyopathy in mice.
    Fischer VW; LaRose LS; Wang GM
    Drug Chem Toxicol; 1982; 5(2):155-64. PubMed ID: 7128476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of daunomycin toxicity by razoxane.
    Wang G; Finch MD; Trevan D; Hellmann K
    Br J Cancer; 1981 Jun; 43(6):871-7. PubMed ID: 7248163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits.
    Herman EH; Ferrans VJ; Jordan W; Ardalan B
    Res Commun Chem Pathol Pharmacol; 1981 Jan; 31(1):85-97. PubMed ID: 6789416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of ICRF-159 or ICRF-186 on cytotoxicity of daunorubicin and doxorubicin.
    Supino R
    Tumori; 1984 Apr; 70(2):121-6. PubMed ID: 6730012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters.
    Herman E; Ardalan B; Bier C; Waravdekar V; Krop S
    Cancer Treat Rep; 1979 Jan; 63(1):89-92. PubMed ID: 421236
    [No Abstract]   [Full Text] [Related]  

  • 7. Potentiation of doxorubicin cytotoxicity by (+)-1,2-bis-(3,5-dioxopiperazinyl-1-yl) propane (ICRF-187) in human leukemic HL-60 cells.
    Monti E; Sinha BK
    Cancer Commun; 1990; 2(4):145-9. PubMed ID: 2164412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction by ICRF-187 of acute daunorubicin toxicity in Syrian golden hamsters.
    Herman EH; El-Hage AN; Ferrans VJ; Witiak DT
    Res Commun Chem Pathol Pharmacol; 1983 May; 40(2):217-31. PubMed ID: 6410471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of some of the toxic effects of daunomycin (NSC-82,151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129,943).
    Herman EH; Mhatre RM; Chadwick DP
    Toxicol Appl Pharmacol; 1974 Mar; 27(3):517-26. PubMed ID: 4212173
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of the protective effect of ICRF-187 and structurally related analogues against acute daunorubicin toxicity in Syrian golden hamsters.
    Herman EH; el-Hage AN; Creighton AM; Witiak DT; Ferrans VJ
    Res Commun Chem Pathol Pharmacol; 1985 Apr; 48(1):39-55. PubMed ID: 3922023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).
    Woodman RJ; Cysyk RL; Kline I; Gang M; Venditti JM
    Cancer Chemother Rep; 1975; 59(4):689-95. PubMed ID: 1175163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig.
    Perkins WE; Schroeder RL; Carrano RA; Imondi AR
    Br J Cancer; 1982 Oct; 46(4):662-7. PubMed ID: 6814473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
    Alderton P; Gross J; Green MD
    Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells.
    Hasinoff BB; Yalowich JC; Ling Y; Buss JL
    Anticancer Drugs; 1996 Jul; 7(5):558-67. PubMed ID: 8862724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin.
    Giuliani F; Casazza AM; Di Marco A; Savi G
    Cancer Treat Rep; 1981; 65(3-4):267-76. PubMed ID: 6263470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
    Herman EH; Zhang J; Hasinoff BB; Chadwick DP; Clark JR; Ferrans VJ
    Cancer Chemother Pharmacol; 1997; 40(5):400-8. PubMed ID: 9272116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of cardiotoxic, nephrotoxic and neurotoxic effects of doxorubicin by ICRF-159.
    Tian Hu S; Brändle E; Zbinden G
    Pharmacology; 1983; 26(4):210-20. PubMed ID: 6844396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of capping of surface immunoglobulins at femtomolar concentrations of adriamycin, compound ICRF-159 and tetrodotoxin [proceedings].
    Gosálvez M; Pezzi L; Vivero C
    Biochem Soc Trans; 1978; 6(3):659-61. PubMed ID: 669043
    [No Abstract]   [Full Text] [Related]  

  • 19. ICRF 159-induced cell-cycle perturbation in vitro: its relationship to inhibition of colony-forming ability.
    Edgar DH; Creighton AM
    Br J Cancer; 1981 Aug; 44(2):236-40. PubMed ID: 7023524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of ICRF 159 on adriamycin-induced cardiomyopathy in rats.
    Decorti G; Bartoli Klugmann F; Mallardi F; Klugmann S; Benussi B; Grill V; Baldini L
    Cancer Lett; 1983 May; 19(1):77-83. PubMed ID: 6406045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.